Comments
The US Food and Drug Administration has granted a priority review status to Roche’s immunotherapy to treat advanced bladder cancer, the Swiss pharmaceutical maker said on Tuesday.
The drug, atezolizumab, was granted the status based on results of a study, which showed the drug shrank tumors and that a majority of patients continued to respond to the treatment after nearly a year of follow up, Roche Chief Medical Officer Sandra Horning said.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.